Collaboration between pharmaceutical companies and patient advocates often requires both parties to sign contracts that define the terms and conditions of the collaboration, covering such matters as confidentiality, intellectual property, copyright, data protection, compensation and other responsibilities of both parties. However, the contracts provided to patient advocates are often too long, and are difficult to understand. They contain ambiguous clauses, or terms that are in conflict with the very nature of patient advocacy. They may even put the signing patient advocate at legal risk.
Myeloma Patients Europe (MPE), the Workgroup of European Cancer Patient Advocacy Networks (WECAN), a network of 20 pan-European cancer patient organisations, along with Patient Focused Medicine Development (PFMD), has initiated the project “Reasonable agreements between patient advocacy and the pharmaceutical industry (RAPP)”. The project is analysing legal contracts between patients’ organisations and pharmaceutical companies, with the aim of evaluating the content of their clauses bearing in mind what a reasonable contract should look like. The main goal is that patient advocates and patient organisations will collaborate with pharmaceutical companies to develop tools that can make the legal relationship between both parties easier and more acceptable.
If you want to know more about this project or be involved in it, please visit the website of this initiative clicking here.